![Stephen Doberstein](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Stephen Doberstein
Director/Board Member at
Invea Therapeutics, Inc.
Profile
Dr. Stephen K.
Doberstein is an Independent Director at Invea Therapeutics, Inc. and a Principal at Kahiliholo Consulting LLC.
He is on the Board of Directors at Invea Therapeutics, Inc. Dr. Doberstein was previously employed as an Independent Director by Forte Biosciences, Inc., an Independent Director by Dicerna Pharmaceuticals, Inc., a Chief Scientific Fellow & Senior Vice President by Nektar Therapeutics, a Vice President-Research by XOMA Royalty Corp., a Vice President-Research by Five Prime Therapeutics, Inc., a Vice President-Research by Xencor, Inc., a Director-Pharmaceutical Target Research by Exelixis, Inc., and an Engineer by EIDP, Inc. He also served on the board at Parmedics, Inc. He received his undergraduate degree from the University of Delaware and a doctorate degree from The Johns Hopkins University School of Medicine.
Stephen Doberstein active positions
| Companies | Position | Start |
|---|---|---|
Kahiliholo Consulting LLC | Corporate Officer/Principal | 2020-01-31 |
Invea Therapeutics, Inc.
 Invea Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases, or IMIDs | Director/Board Member | 2024-11-30 |
Former positions of Stephen Doberstein
| Companies | Position | End |
|---|---|---|
| FORTE BIOSCIENCES | Director/Board Member | 2026-08-26 |
| DICERNA PHARMACEUTICALS, INC. | Director/Board Member | 2021-12-27 |
| NEKTAR THERAPEUTICS | Chief Tech/Sci/R&D Officer | 2020-02-29 |
| FIVE PRIME THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2008-09-30 |
| XENCOR, INC. | Chief Tech/Sci/R&D Officer | 2004-06-30 |
Education of Stephen Doberstein
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
57
1st degree connections
12
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 12 |
|---|---|
EIDP, Inc.
 EIDP, Inc. Chemicals: AgriculturalProcess Industries Manufactures and sells seed & crop protection products | Process Industries |
Nektar Therapeutics
 Nektar Therapeutics Pharmaceuticals: MajorHealth Technology Discovers and develops medicines in areas of high unmet medical need | Health Technology |
XOMA Royalty Corp.
 XOMA Royalty Corp. Pharmaceuticals: MajorHealth Technology Discovers and develops antibody therapeutics | Health Technology |
Exelixis, Inc.
 Exelixis, Inc. Pharmaceuticals: MajorHealth Technology Operates as a cancer drug discovery company | Health Technology |
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops protein therapeutics for cancer and inflammatory diseases | Health Technology |
Xencor, Inc.
 Xencor, Inc. BiotechnologyHealth Technology Develops therapeutics to treat autoimmune and allergic diseases, cancer and other conditions | Health Technology |
Dicerna Pharmaceuticals, Inc.
 Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that focuses on discovering, developing and commercializing medicines for chronic liver diseases | Health Technology |
University of Delaware
 University of Delaware Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Johns Hopkins University School of Medicine
 The Johns Hopkins University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Forte Biosciences, Inc.
 Forte Biosciences, Inc. BiotechnologyHealth Technology Provides dermatological therapies and related services | Health Technology |
Invea Therapeutics, Inc.
Invea Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases, or IMIDs | Health Technology |
Kahiliholo Consulting LLC |
- Stock Market
- Insiders
- Stephen Doberstein
